3 completed, 2 active not recruiting, 2 recruiting, 1 terminated. 9 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Active not recruiting 2, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Advanced Head and Neck Squamous Cell Carcinoma: new trials by email Literature Review of Advanced Head and Neck Squamous Cell Carcinoma trials Research Report on Advanced Head and Neck Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 28 | 2025-11-18 | 2026-06-26 |
| A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers HMBD-001, Docetaxel, Cetuximab - Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Hummingbird Bioscience | 398 | 2024-02-05 | 2026-05-27 |
| PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma Pembrolizumab, MET-4, Placebo - Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | Canadian Cancer Trials Group | 2023-05-12 | 2023-05-18 | |
| A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®] - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer | Phase 1 / Phase 2 | Completed | Cytovation AS | 6 | 2023-03-21 | 2025-11-28 |
| Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer Cisplatin, Computed Tomography, Magnetic Resonance Imaging - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 475 | 2022-02-01 | 2026-10-23 |
| Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC Duvelisib, Docetaxel - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed | Kartik Sehgal, MD | 26 | 2021-10-14 | 2026-09-29 |
| Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition Pembrolizumab (immunotherapy), Quad-shot palliative radiotherapy - Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Wake Forest University Health Sciences | 21 | 2021-02-25 | 2025-11-19 |
| A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma CDX-3379 and cetuximab - Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Celldex Therapeutics | 30 | 2018-03-27 | 2023-04-03 |
| CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab - Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 51 | 2016-12-22 | 2026-08-10 |
Squamous Cell Carcinoma of Head and Neck (5) · Carcinoma, Non-Small-Cell Lung (2) · Oropharyngeal Neoplasms (2) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Laryngeal Neoplasms (1) · Lung Neoplasms (1) · Mouth Neoplasms (1) · Neoplasms (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Carcinoma (5) · Head and Neck Neoplasms (5) · Carcinoma, Squamous Cell (4) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Otorhinolaryngologic Diseases (2) · Otorhinolaryngologic Neoplasms (2) · Pharyngeal Diseases (2)
pembrolizumab (4) · Cetuximab (2) · Docetaxel (2) · Magnetic Resonance Spectroscopy (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Biopsy (1) · CIMAvax EGF (1) · Cisplatin (1) · Immunotherapy (1) · Nivolumab (1) · Platinum (1) · Radiation (1) · Radiotherapy (1) · Specimen Handling (1) · Surgical Procedures, Operative (1)
Canadian Cancer Trials Group (1) · Celldex Therapeutics (1) · Cytovation AS (1) · Hummingbird Bioscience (1) · Kartik Sehgal, MD (1) · NRG Oncology (1) · Roswell Park Cancer Institute (1) · University of Michigan Rogel Cancer Center (1) · Wake Forest University Health Sciences (1)
United States (7) · Australia (1) · Canada (1) · France (1) · Hong Kong (1) · Ireland (1) · Italy (1) · Moldova (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Switzerland (1) · Taiwan (1)
Anna Spreafico (1) · Kartik Sehgal, MD (1) · Mercedes Porosnicu, MD (1) · Paul L Swiecicki (1) · Paul M Harari (1) · Prantesh Jain, MD (1)
PMID 31308059, PMID 37199326, PMID 42313403
P30CA012197 (1), U10CA180868 (1)